Genflow Biosciences plc
GENF.L · LSE
6/30/2025 | 3/31/2025 | 12/31/2024 | 12/31/2023 | |
|---|---|---|---|---|
| Revenue | £123 | £123 | -£396 | -£97 |
| % Growth | 0% | 130.9% | -308.2% | – |
| Cost of Goods Sold | £0 | £0 | £0 | £1 |
| Gross Profit | £123 | £123 | -£396 | -£98 |
| % Margin | 100% | 100% | 100% | 100.6% |
| R&D Expenses | £333 | £333 | £107 | £545 |
| G&A Expenses | £471 | £471 | £271 | £523 |
| SG&A Expenses | £491 | £491 | £296 | £437 |
| Sales & Mktg Exp. | £20 | £20 | £24 | £32 |
| Other Operating Expenses | -£333 | -£333 | -£427 | £0 |
| Operating Expenses | £491 | £491 | -£25 | £982 |
| Operating Income | -£369 | -£369 | -£371 | -£983 |
| % Margin | -300.9% | -300.9% | 93.7% | 1,013.1% |
| Other Income/Exp. Net | £0 | £0 | -£160 | -£24 |
| Pre-Tax Income | -£369 | -£369 | -£531 | -£1,007 |
| Tax Expense | £0 | £0 | £0 | £0 |
| Net Income | -£369 | -£369 | -£531 | -£1,007 |
| % Margin | -300.9% | -300.9% | 134.2% | 1,038% |
| EPS | -0.001 | -0.001 | -0.002 | -0.003 |
| % Growth | 0% | 33.3% | 55.9% | – |
| EPS Diluted | -0.001 | -0.001 | -0.002 | -0.003 |
| Weighted Avg Shares Out | 384,577 | 384,577 | 351,049 | 292,507 |
| Weighted Avg Shares Out Dil | 384,282 | 384,282 | 350,834 | 292,507 |
| Supplemental Information | – | – | – | – |
| Interest Income | £0 | £0 | £0 | £0 |
| Interest Expense | £0 | £0 | £0 | £0 |
| Depreciation & Amortization | £0 | £0 | £0 | £1 |
| EBITDA | -£369 | -£369 | -£531 | -£982 |
| % Margin | -300.7% | -300.7% | 134.1% | 1,012.5% |